Nephrocare Health Services reported a 23.5% year-on-year revenue growth for the second quarter of FY27, reaching INR303 crores. The company highlighted healthy growth in its H1 FY27 numbers and outlined strategic initiatives including expansion into Kazakhstan, qualification for a Saudi Arabia tender, and the launch of the NephroPlus International Dialysis Academy (NIDA). Management reiterated its medium-term guidance of 15-20% revenue growth over three to four years.
Nephrocare Health Services Announces Q2 FY27 Financial Results
Nephrocare Health Services Limited has announced its financial results for the second quarter and first half of fiscal year 2027. The company reported a 23.5% year-on-year revenue growth for Q2 FY27, with revenues reaching INR303 crores. For the first half (H1) of FY27, revenue stood at INR585 crores, marking a 24% increase over the previous year. This performance reflects the company’s continued healthy growth trajectory, building upon strong H1 FY27 numbers.
Strategic Growth Initiatives and Market Expansion
During the investor conference call, management highlighted several key strategic developments. The company successfully launched its NephroPlus network in Kazakhstan, marking the opening of a new geography and a significant growth lever. Additionally, Nephrocare Health Services has technically qualified for a tender from Saudi Arabia’s Ministry of Health, positioning itself as one of the 12 eligible bidders for a substantial portion of the country’s dialysis patients. The company also launched NIDA, the NephroPlus International Dialysis Academy, aimed at training nurses for the global dialysis market to address supply shortages.
Operational Performance and Network Growth
Rohit Singh, Group Chief Executive Officer, detailed the operational performance, stating that the network now comprises 570 clinics across six countries, with 500 in India and 70 internationally. The company added clinics in India and the Philippines during the half and entered Kazakhstan. India remains its largest market, serving over 33,000 guests, with a strong focus on tier 2 and tier 3 towns. The Philippines network expanded to over 55 clinics.
Financial Highlights and Guidance
Prashant Goenka, Group Chief Financial Officer, provided insights into the financial metrics. Adjusted EBITDA for H1 FY27 was INR134 crores, with a margin of 23%. For Q2 FY27, adjusted EBITDA stood at INR68.9 crores, a 3.3% increase year-on-year. The company noted that year-on-year margin comparisons should be viewed considering its transition to a listed company with quarterly audits. Nephrocare Health Services reiterated its medium-term guidance of 15% to 20% revenue growth over three to four years, emphasizing disciplined returns as it continues its growth strategy both domestically and internationally.
Source: BSE
